Status:

UNKNOWN

Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.

Lead Sponsor:

Shandong University

Collaborating Sponsors:

Peking University Care Luzhong Hospital

Zibo Central Hospital

Conditions:

Helicobacter Pylori Infection

Eligibility:

All Genders

18-70 years

Phase:

PHASE4

Brief Summary

The researchers collect H.pylori-positive patients who need rescue therapy from the outpatient clinic. The subjects were randomized to receive a dose and frequency of tetracycline 500mg tid or qid of ...

Detailed Description

The researchers collect H.pylori-positive patients who need rescue therapy from the outpatient clinic. If the subject meets the selection criteria but not the exclusion criteria, and signs an informed...

Eligibility Criteria

Inclusion

  • Patients aged 18-70.
  • Patients with H.pylori infection (Positive for rapid urease test or 13C/14C-urea breath test).
  • Patients who have previous failed H. pylori eradication treatment, and ≤ 2 times.

Exclusion

  • Patients with serious underlying diseases, such as liver insufficiency (Aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the normal value), renal insufficiency (Cr≥2.0mg/dL or glomerular filtration rate \<50 ml/min), immunosuppression, malignant tumors, Coronary heart disease or coronary artery stenosis ≥75%.
  • Patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial.
  • Patients with active gastrointestinal bleeding.
  • Patients with a history of upper gastrointestinal surgery.
  • Patients allergic to treatment drugs.
  • Patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks
  • Patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse
  • Patients who are unwilling or incapable to provide informed consents

Key Trial Info

Start Date :

June 25 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2023

Estimated Enrollment :

407 Patients enrolled

Trial Details

Trial ID

NCT05432115

Start Date

June 25 2022

End Date

October 1 2023

Last Update

January 31 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Qilu Hospital

Jinan, Shandong, China, 250012